ProCE Banner Activity

CE

Enhancing the Use of GLP-1 RAs in Patients With Type 2 Diabetes to Improve Individualized Patient-Centered Care

Multimedia

Expert faculty provide insights on the benefits of GLP-1 receptor agonists for the treatment of type 2 diabetes.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: November 01, 2022

Expiration: October 31, 2023

No longer available for credit.

Share

Faculty

Kristi Kelley

Kristi Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM

Clinical Professor
Department of Pharmacy Practice
Auburn University Harrison College of Pharmacy
Clinical Pharmacist
Baptist Health Foundation Center for Medical and Surgical Care
Princeton Baptist Medical Center/
Brookwood Baptist Health
Birmingham, Alabama

Christie Schumacher

Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP

Professor
Department of Pharmacy Practice
Midwestern University
College of Pharmacy
Downers Grove, Illinois
Clinical Pharmacist
Advocate Medical Group
Chicago, Illinois

Provided by

Provided by ProCE, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Target Audience

The target audience for this program is pharmacists, including clinical, community, ambulatory care, and health-system pharmacists, who care for patients with type 2 diabetes, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the physiologic actions of GLP-1 RAs that contribute to metabolic, renal, and cardiovascular benefits in patients with type 2 diabetes

  • Compare the available GLP-1 RAs with regard to their dosing, administration, glycemic effects, and extraglycemic benefits

  • Develop treatment plans that incorporate GLP-1 RAs early in the management of diabetes based on guideline recommendations, clinical evidence, and individualized patient needs and preferences

  • Devise strategies to improve patient acceptance, tolerance, and adherence to GLP-1 RA treatment

Disclosure

ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy.

ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

 Primary Author

Kristi Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM

Clinical Professor
Department of Pharmacy Practice
Auburn University Harrison College of Pharmacy
Clinical Pharmacist
Baptist Health Foundation Center for Medical and Surgical Care
Princeton Baptist Medical Center/
Brookwood Baptist Health
Birmingham, Alabama

Kristi W. Kelley, PharmD, FCCP, BCPS, BCACP, CDCES, BC-ADM, has no relevant financial relationships to disclose.

Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP

Professor
Department of Pharmacy Practice
Midwestern University
College of Pharmacy
Downers Grove, Illinois
Clinical Pharmacist
Advocate Medical Group
Chicago, Illinois

Christie Schumacher, PharmD, BCPS, BCACP, BCCP, BC-ADM, CDCES, FCCP: consultant/advisor/speaker: Abbott, Dexcom, Novo Nordisk.

The planners and content peer reviewers from ProCE, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-206-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.0 contact hours (0.10 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Additional Information

Program Medium

This program has been made available online.